PBAC Stakeholder Meetings

Record of Stakeholder Meetings

• Multiple Myeloma Sponsor Meeting (February 2026) Outcome Statement (PDF 356KB) - (Word 66KB)
• Pulmonary Arterial Hypertension Stakeholder Meeting (August 2025) Outcome Statement (PDF 722KB) - (Word 64KB)
• Multiple Myeloma Stakeholder Meeting (July 2025) Outcome Statement (PDF 231KB) - (Word 59KB)
• Oral Contraceptives Stakeholder Meeting (October 2024) Outcome Statement (PDF 143KB) – (Word 27KB)
• Migraine Stakeholder Meeting (October 2024) Outcome Statement (PDF 169KB) – (Word 34KB)
• Myasthenia Gravis Stakeholder Meeting (May 2024) Outcome Statement (PDF 277KB) - (Word 31KB)
• Esketamine Stakeholder Meeting (February 2023) Outcome Statement (PDF 237KB) - (Word 29KB)
• Semaglutide Stakeholder Meeting (August 2021) Outcome Statement (PDF 229KB) - (Word 36KB)
• SMA Stakeholder Meeting (December 2020) - Outcome Statement (PDF 626KB) - (Word 36KB)
• Asthma Stakeholder Meeting December 2018 – Outcome Statement (PDF 206KB) - (Word 34KB)
• PD-(L) 1 inhibitors for non-small cell lung cancer (February 2019) (PDF 668KB) - (Word 47KB)
• Direct-acting Antivirals for Hepatitis C (December 2018) (PDF 654KB) - (Word 32KB)
• Multiple Myeloma (May 2018) - (Word 37KB) - (PDF 335KB)
• Nusinersen (Spinraza®) for the treatment of Spinal Muscular Atrophy (January 2018) - (Word 32KB) - (PDF 322KB)
• Eculizumab (Soliris®) for Atypical Haemolytic Uraemic Syndrome (February 2016) - (Word 31KB) - (PDF 264KB)
• New oral antivirals for the Treatment of Hepatitis C (February 2014) - (Word 46 KB) - (PDF 241 KB)
• Eculizumab (Soliris®) for Atypical Haemolytic Uraemic Syndrome (June 2014) - (Word 50 KB) - (PDF 510 KB)
• Metastatic Breast Cancer (May 2014) - (Word 41 KB) - (PDF 46 KB)
• Ruxolitinib for Myelofibrosis (September 2014) - (Word 32 KB) - (PDF 350 KB)
• Nitisinone for tyrosinaemia type 1 (February 2015) (Word 40 KB) - (PDF 63 KB)